Barry Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-9,062
Closed -$553K 105
2025
Q1
$553K Buy
9,062
+52
+0.6% +$3.03K 0.15% 65
2024
Q4
$510K Sell
9,010
-1,612
-15% -$90.1K 0.16% 68
2024
Q3
$550K Sell
10,622
-3,524
-25% -$165K 0.17% 64
2024
Q2
$587K Buy
14,146
+2,794
+25% +$125K 0.2% 65
2024
Q1
$616K Sell
11,352
-315
-3% -$16K 0.21% 61
2023
Q4
$599K Sell
11,667
-118
-1% -$6.19K 0.2% 58
2023
Q3
$684K Buy
11,785
+19
+0.2% +$1.16K 0.25% 58
2023
Q2
$752K Sell
11,766
-751
-6% -$50.4K 0.25% 60
2023
Q1
$868K Sell
12,517
-156
-1% -$11K 0.28% 54
2022
Q4
$912K Sell
12,673
-459
-3% -$34.6K 0.29% 54
2022
Q3
$934K Sell
13,132
-53
-0.4% -$3.85K 0.32% 46
2022
Q2
$1.01M Sell
13,185
-246
-2% -$18.7K 0.3% 50
2022
Q1
$981K Sell
13,431
-159
-1% -$10.7K 0.26% 55
2021
Q4
$847K Buy
13,590
+1,791
+15% +$105K 0.22% 56
2021
Q3
$698K Buy
11,799
+463
+4% +$30.5K 0.19% 56
2021
Q2
$757K Buy
11,336
+2,006
+22% +$131K 0.2% 59
2021
Q1
$589K Buy
9,330
+2,352
+34% +$146K 0.16% 65
2020
Q4
$433K Buy
+6,978
New +$429K 0.13% 70

Other funds holding BMY

Barry Investment Advisors's BMY Position: Q2 2025 in Review

Barry Investment Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 9,062 shares — an estimated $553K sold.

Barry Investment Advisors first reported a position in BMY in Q4 2020 and held it in 18 quarters. The position peaked at $1.01M in Q2 2022. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • Barry Investment Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
  • Barry Investment Advisors sold 9,062 Bristol-Myers Squibb shares in Q2 2025, an estimated $553K.
  • Barry Investment Advisors first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 18 quarters.
  • Barry Investment Advisors's Bristol-Myers Squibb position peaked at $1.01M in Q2 2022.
  • 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Barry Investment Advisors's 13F filing for Q2 2025, filed 17 Jul 2025.